Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Silynxcom Unveils Innovative Headset to Enhance Drone Detection for Armored Vehicle Crews
-
FTI Consulting Survey Identifies Renewed Optimism as Healthcare & Life Sciences Sector Embarks on 2025
-
FTI Consulting Survey Identifies Renewed Optimism as Healthcare & Life Sciences Sector Embarks on 2025
-
Midland, in Partnership With RTEC, Continues to Intersect Spodumene Pegmatites on the Galinée Project
-
HPQ Silicon Signs Agreement to Strengthen its Balance Sheet
-
VR Resources Outlines Large 3D Chargeability Anomaly at the Silverback Copper-Gold Project in Ontario
-
Amesite Announces AI-Powered NurseMagic™ Growth in Marketing Reach to Key Markets and Meteoric Rise in Social Media Engagement
-
Altimmune Added to Nasdaq Biotechnology Index
-
Fancamp Receives Shares of Canadian Gold Resources and Finalizes Transfer of Robidoux Property
-
SL Green Realty Corp. to Release Fourth Quarter 2024 Financial Results After Market Close on January 22, 2025
-
ZenaTech’s ZenaDrone Moves to a New Arizona Manufacturing Facility for US Defense Focused on Drone Swarms Using Quantum Computing
-
Dragonfly Energy Partners with Stevens Transport, Inc. to Transition Entire Fleet to Hybrid Battery Solutions
-
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorecta
-
FuelCell Energy Reports Fourth Quarter and Full Fiscal Year 2024 Results
-
XOMA Royalty Declares Quarterly Preferred Stock Dividends
-
SweetWater Brewing Announces 28th Anniversary Bash With STS9 Headlining an Immersive Jamtronica Experience
-
Stardust Power Appoints Martyn Buttenshaw to Board of Directors
-
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
-
Correction: Annual Report 2023/24
-
El Sapo Pepe $PEPE: The First Pepe That Inspired Matt Furie's Pepe
-
El Sapo Pepe $PEPE: The First Pepe That Inspired Matt Furie's Pepe
-
Microbix Reports Record Product Sales for Q4 and Fiscal 2024
-
EnviroGold Global Announces Private Placement
-
Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye
-
Holding(s) in Company
-
NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate
-
BexBack Futures Exchange: 100% Deposit Bonus and No KYC—The Freedom Every Trader Deserves
-
Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment
-
Western Investment Company Closes Outstanding $1.1 Million of the $30 Million Over-Subscribed Private Placement
-
Nevada Lithium Announces Conditional Approval of TSX Venture Exchange Uplisting
-
XORTX Strengthens Executive Team
-
Skye Bioscience to Present at J.P. Morgan Healthcare Conference
-
Lantronix to Present at the 27th Annual Needham Growth Conference on Jan. 14–15, 2025
-
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
-
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
-
Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference
-
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
-
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
-
Arbor Biotechnologies Announces FDA Acceptance of IND Application for ABO-101 for the Treatment of Primary Hyperoxaluria Type 1
-
NMD Pharma Announces Publication of Phase 1 Clinical Trial Data Evaluating NMD670 in Healthy Volunteers in the Journal Clinical Pharmacology & Therapeutics
-
NewGen Engages OSL to Execute Strategic Investment in Digital Assets
-
AleAnna Announces Signing of Gas Sale Contract with Shell Energy Europe
-
PyroGenesis Announces Debt-to-Equity Conversion of Client Receivable
-
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
-
Climb Bio to be Added to the Nasdaq Biotechnology Index
-
FactSet Reports Results for First Quarter 2025
-
Tilray Brands, Inc. to Announce Second Quarter Fiscal Year 2025 Financial Results on January 9, 2025
-
Conavi Medical Reports Fiscal 2024 Financial Results and Operational Highlights
-
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
-
OTC Markets Group Welcomes Metaplanet Inc. to OTCQX
